APPOINTMENT OF MEDIPROUD CO., LTD AS NON-EXCLUSIVE DISTRIBUTOR FOR BIOLIDICS&rsquo NOVEL CORONAVIRUS 2019 ANTIBODY TEST KITS

The board of directors (the " Board" or the " Directors" ) of Biolidics Limited (the " Company" , and together with its subsidiaries, the &ldquo Group&rdquo ) is pleased to announce that the Company had, on 7 May 2020, entered into a distribution agreement (the " Agreement" ) with Mediproud Co., Ltd (" Mediproud" ), a company incorporated in Thailand, to appoint Mediproud as a non-exclusive distributor for the Company&rsquo s test kits for the detection of the Novel Coronavirus 2019 antibodies (the " COVID-19 Antibody Test Kits" ), in Thailand for a duration of one year from the date of the Agreement. The Company&rsquo s COVID-19 Antibody Test Kits are for the qualitative detection of the antibodies to SARS-CoV-2 (the virus which causes the disease, the Novel Coronavirus 2019), IgG and IgM, in human serum, plasma and whole blood.
​
Under the terms of the Agreement, among others, Mediproud shall assist the Company to obtain all permits, licenses, registrations and consents from the applicable authorities in order to import and sell the COVID-19 Antibody Test Kits in Thailand. Mediproud is in the process of obtaining the Thailand Food and Drug Administration&rsquo s (" Thailand FDA" ) authorisation to offer the COVID-19 Antibody Test Kits in Thailand. The use of the COVID-19 Antibody Test Kits in Thailand will be limited to testing in laboratories or by healthcare workers at the point-of-care.

Incorporated in 2015, Mediproud is a distributor of medical equipment and tools in Thailand. For more information on Mediproud, please visit https://www.mediproud.com/home.

The Agreement is likely to contribute positively to the revenue of the Group for the current financial year ending 31 December 2020 (" FY2020" ). However, the Company is unable to quantify the financial impact for FY2020 as the volume and timing of the orders by Mediproud cannot be determined as at the date of this announcement.

Shareholders and potential investors should note that the import and sale of the Company&rsquo s COVID- 19 Antibody Test Kits in Thailand is subject to its COVID-19 Antibody Test Kits obtaining all permits, licenses, registrations and consents from the applicable authorities in Thailand, and in particular, the authorisation of the Thailand FDA (" Regulatory Approvals" ). There is no certainty that such Regulatory Approvals will be obtained.

Further, shareholders and potential investors should note that policies in relation to diagnosis and/or detection of the Novel Coronavirus 2019 virus and/or antibodies in various jurisdictions may change in response to developments in the COVID-19 situation which is evolving rapidly. Shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company and should consult their stockbrokers, bank managers, solicitors, accountants or other professional advisers if they are in doubt about the actions that they should take.

Save for their respective shareholdings in the Company (if any), the Company is not aware of any of its Directors or substantial shareholders having any interest, direct or indirect in the Agreement.